DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Piccart M, Procter M, Fumagalli D. et al. APHINITY Steering Committee and Investigators.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Yearsʼ Follow-Up.
J Clin Oncol 2021;
DOI: 10.1200/JCO.20.01204.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.